Physician profile
John A Clay
NPI 1093905994
$40,343.07
in general payments reported to CMS, 2019-2025
45 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $241 · 2021: $444 · 2022: $598 · 2023: $3,941 · 2024: $16K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $4,971 · Travel and Lodging: $1,236 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,400.00 |
| Food and Beverage | $4,971.17 |
| Travel and Lodging | $1,235.94 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34,203.06 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $944.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $644.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $478.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $464.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $315.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $311.67 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.55 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $254.57 | 2019-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $183.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $167.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $162.21 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $159.80 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $151.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $147.11 | 2023-2024 | Uptravi, Opsumit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.